SecBot SecBot
8-K ·Filed Aug 13, 2026

INDP

Indaptus Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago SEC0001493152-26-037574
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The company is a pre-revenue clinical-stage biotech with no active pipeline, now a cash-rich shell seeking a strategic transaction. Monitor for announcements of a reverse merger, acquisition target, or new research partnership. The $12M raise provides a runway for deal-making, but the stock is purely a binary event play on management's ability to execute a pivot.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.06
T+0 close · Aug 13, 2026 · via day close
Latest settled
+213.21%
T+60 · $3.32
Vs SPY
+218.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $1.06entry
  2. T+1 · 3mo ago +0.94%α +1.14% · $1.07
  3. T+5 · 3mo ago +30.19%α +32.15% · $1.38
  4. T+20 · 2mo ago +161.32%α +163.07% · $2.77
  5. T+60 · 11d ago +213.21%α +218.68% · $3.32
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Indaptus Therapeutics reported Q2 2026 results with no active clinical programs, having discontinued its Decoy20 study. Net loss narrowed to $1.8M from $5.2M YoY, driven by cost cuts. The company raised $12M in a June private placement, boosting cash to ~$11.6M, but is now a cash-burning shell evaluating strategic alternatives, including potential acquisitions or investments in new research areas like neurological disorders. The stock is a speculative story on the company's ability to execute a pivot, with no pipeline value.

Key Financial Metrics

EPS
−$0.02
Revenue
$0.00
est $0.00 · 0.0%
Rating
in line

Key Facts

  • Net loss for Q2 2026 was $1.8M, down from $5.2M in Q2 2025.
  • Cash, cash equivalents, and short-term investments totaled $11.6M as of June 30, 2026.
  • Completed a $12.0M private placement on June 17, 2026, issuing 20M shares at $0.60/share.
  • Discontinued further enrollment in the Decoy20 combination study; no active clinical development programs.
  • Began a research collaboration in neurological disorders and sleep as an extension of immunotherapy research.
  • All outstanding Series AA and Series AAA Preferred Stock converted into common stock during Q1 2026.
  • Annual meeting held August 10, 2026; all director nominees elected and 2026 Equity Incentive Plan approved.

Financial Impact

Net loss improved by $3.4M YoY to $1.8M; cash position strengthened by $12M private placement to $11.6M.

cashnet lossdilution

Risk Factors

  • No active clinical programs or revenue; company is a cash-burning shell.
  • Dilution from the 20M-share June private placement (shares outstanding rose from 2.2M to 133.2M post-split).
  • Going concern risk remains if a strategic transaction is not consummated before cash is depleted.
  • Nasdaq continued-listing risk cited in forward-looking statements.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-037574
Document: form8-k.htm0001493152-26-037574
Document: 0001493152-26-037574-index-headers.html0001493152-26-037574
Document: 0001493152-26-037574-index.html0001493152-26-037574
Document: 0001493152-26-037574.txt0001493152-26-037574
8-K Data (Synthetic)0001493152-26-037574

Track record

20 reports on INDP

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 6 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
  2. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  3. Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  4. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  5. Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
  6. Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
  8. Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
  9. Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
  10. Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026